| Mission |
| Biological targets |
| Indications & Disease Mechanisms |
| From bench to bedside |
| A virtual institute |
| Members |
| Technology leaders & SDR/HSD links |
| Contact, Imprint & Copyright |
InnVentis: Bringing innovative ideas to live
Symbiotic Innovation:
Modular, web-based gathering of scientific leaders enables value growth
download pdf for cornerstone insight, proprietary tools and value creation approaches are not divulged)
(download Presentation; Fullview animated mode translates key topics best)
Transcriptional Science: Improving efficacy in R&D and enabling Translational Sciences by data extraction and elimination of bias and dogmas)
(download Presentation; Fullview animated mode translates key topics best)
InnVentis business model: First of all, Symbiotic Innovation is a new business model, based on pro-active research to identify solutions and an optimized value creation concept from biomedical research and science in research intensive industries in general. Symbiotic Innovation claims to secure value creation from science with an innovative managed risk/revenue sharing concept. InnVentis created a motivation and revenue/reward-driven, WWW-based virtual business model that optimally leverages risk, resources and reduces time within an ever complext technological and financial environment. Symbiotic Innovations creates significant ROI (financial and products) as well as added value to all participants in the value chain by the optimized use of established resources and mechanisms such as "collective learning" in networks assembling leaders in their fields from industry and academia. To the best of our knowledge, there has been no comparable pro-active research project at any academic or industrial site to develop a new optimized value creation concept starting from the comprehensive analysis of the literature on problems, challenges and complexities (both scientific and socioeconomic) and with the use of the WWW (Blogs, Postings) and Opinion Leader's feed-back to address the innovation gap in drug discovery and their origins identified in the last years. The research project to develop Symbiotic Innovation lasted over three years since 1/2007 and claims to provide one alternative to existing anatomies and business models that failed to deliver ROI to investors, society and tax payers, i.e. all stake holders in health care. InnVentis proposes that currently all "new" approaches must be regarded experiments, since they lack validation, but Symbiotic Innovation is the only concept, developed without bias or the requirement to comply with external or internal interests, but on the basis of 10 years experience with a virtual company and additional three years pro-active research. InnVentis aims to become the leading partner for value creation in drug discovery to PoC in human disease in an environment the will be dominated by the optimal use of the WWW and opportunities arising from this revolution in communication and collaboration. InnVentis currently looks for a project Sponsor (see presentations for definitions) and an affiliation with an academic institution leading in socioeconomic sciences to further evaluate and improve Symbiotic Innovation, i.e. an academic institution that accopmanies the implementation and execution. Off note Symbiotic Innovation is significantly different from Open Innovation and concept like InnoCentive, but is based on their leadership in Open Innovation and experience, that scientist and other players in drug discovery wish to proactively engage in value creation from basic research. Symbiotic Innovation aims to complement Open Innovation and fill the gap, where Open innovation cannot be used due to the necessity to protect knowledge, trade secrets and IP, while the value creation process depends on iterative matrix processes; i.e. Symbiotic Innovation addresses research intensive industries beyond the pharmaceutical industry. Since InnVentis can at present only address one project and/or disease at a time, InnVentis offers flexible consulting services for translational research projects and it's proprietary Symbiotic Innovation concept, ranging from project review to the full implementation and orchestration of a project in a joint effort between the sponsor and academic sites. Consulting includes discussions and support to adopt InnVentis' concepts such as Symbiotic Innovation and Transcriptional Sciences to other environments and project visions and adjusting Symbiotic Innovation to specific scientific and organizational requirements. This includes the introduction of Transcriptional Science as a tool to secure hypothesis building, project selection and decision making at the best informed level of confidence and trust in data that comply to the translational paradigm, as well as other proprietary concepts. We aim to offer SI as a solution to industry leaders in order to establish, validate and improve Symbiotic Innovation. In this context Transcriptional Science, is only one solution and tool that has been identified, but itself creates commercial as well as academic value in the long run. Transcriptional Science may serve as an example, that we can provide detailed, sometime patentable solutions as a result of our extensive work and research into the factors that not only hinder innovation, but also cause late stage failure. Scientific context for InnVentis' products and concept implementation (proprietary NCEs): Ideally InnVentis would develop its own products, NCEs on the basis of 22 years scientific research, previous networks and access to leadership knowledge, but remains opportunistic to implement Symbiotic Innovation as the prime business and value creation basis for clients, sponsors and partners.
Markets and targets: Pathway focussed translational, biomedical sciences & drug discovery.
Nuclear steroid hormone receptors, co-modulators and hydroxysteroid dehydrogenases (HSDs).Steroid-hormone deriving therapies are based on mechanisms that comprise exquisitely drugable target classes with implications for unmeet medical needs; i.e. type II diabetes, metabolic syndrome, cancer, endocrine-related diseases as well inflammation/immunity, angiogenesis, cardiovascular diseases and bone loss.
|